NEFA (drug)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Wbm1058 (talk | contribs) at 16:47, 26 February 2018 (+hyphen (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

NEFA
Identifiers
  • (4aR,9aS)-N-Ethyl-4,4a,9,9a-tetrahydro-1H-fluoren-4a-amine
PubChem CID
Chemical and physical data
FormulaC15H19N
Molar mass213.3181 g/mol g·mol−1
3D model (JSmol)
  • CCNC12CC=CCC1CC3=CC=CC=C23
  • InChI=1S/C15H19N/c1-2-16-15-10-6-5-8-13(15)11-12-7-3-4-9-14(12)15/h3-7,9,13,16H,2,8,10-11H2,1H3/t13-,15+/m0/s1
  • Key:DRCWOKJLSQUJPZ-DZGCQCFKSA-N
  (verify)

NEFA is a moderate affinity NMDA antagonist (IC50 = 0.51 μM). It is a structural analog of phencyclidine.[1] It was first synthesized by a team at Parke-Davis in the late 1950s.[2]

References

  1. ^ Dilmore JG, Johnson JW (1998). "Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine". Biophysical Journal. 75 (4): 1801–16. doi:10.1016/S0006-3495(98)77622-2. PMC 1299852. PMID 9746522.
  2. ^ GB Patent 893920 - Polycyclic amino compounds and methods for their production